Trial Profile
Renal effects of levosimendan in patients admitted with acute decompensated heart failure
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Levosimendan (Primary)
- Indications Decompensated heart failure
- Focus Pharmacodynamics
- 01 Sep 2010 Results presented at the ESC Congress 2010: Annual Congress of the European Society of Cardiology
- 01 Sep 2010 Status changed from not yet recruiting to active, no longer recruiting.
- 17 Sep 2007 New trial record.